Personalized Anti-Rejection Therapy with Alemtuzumab for Kidney Transplant Recipients

Hesselink, Dennis A.; Hullegie-Peelen, Daphne M; Vugt, Lukas K van

doi:10.2217/pgs-2022-0071

Cited by 1 publication

(1 citation statement)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Taken together these recent studies suggest that follow-up studies on the relation between alemtuzumab PK, lymphocyte dynamics and clinical outcomes are warranted to further substantiate the clinical potential and rationale for personalized alemtuzumab therapy in kidney transplantation [40]. And as pointed out in an editorial [42]: the combination of clinical and histologic data with molecular analysis of renal allograft biopsies and pharmacokinetic data of the drug of interest is the way forward.…”

Section: Alemtuzumabmentioning

confidence: 98%

TDM of belatacept and other biologicals in transplantation.

Bergan,

Vethe

2024

Preprint

View full text Add to dashboard Cite

In solid organ transplantation biologicals like recombinant therapeutic proteins, monoclonal antibodies, fusion proteins and conjugates are increasingly used for immunosuppression, desensitization, ABO incompatibility, antibody mediated rejections and atypical hemolytic uremic syndrome. For some of these drugs this represents off-label use; and the evidence to define their role in current therapies and the evidence for their clinical benefit may be sparse. Biologicals are large molecules compared to traditional drugs, and the processes that define their pharmacokinetics are different. Validated drug assays that can be applied in clinical routine are to a large extent available. Dosing is currently mostly standard -either fixed doses or adjusted according to body size; and when drug concentrations have been measured, large variability in distribution and elimination has been demonstrated. This opens for the proposal to identify optimal concentration ranges, establish PK/PD models for interpretation and guidance, leading to model informed precision dosing. Extrapolation of the results from use of these drugs on other indications may provide some of the necessary information. For drugs like alemtuzumab, eculizumab, rituximab, tocilizumab and belatacept there may be a potential for model informed precision dosing. However, for all of these the challenge is to perform studies that are properly designed to provide evidence for beneficial outcome related to the individualization of treatment. This calls for collaboration within the transplantation and TDM community.

show abstract

Section: Alemtuzumabmentioning

confidence: 98%